Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR 920.30
-4.45 (-0.48%)
May 30, 2025, 10:30 AM IST
Zydus Lifesciences Revenue
In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B INR with 18.90% growth. Zydus Lifesciences had revenue of 65.28B in the quarter ending March 31, 2025, with 17.96% growth.
Revenue
232.42B
Revenue Growth
+18.90%
P/S Ratio
4.00
Revenue / Employee
8.63M
Employees
26,921
Market Cap
930.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 134.58B |
| Fortis Healthcare | 77.83B |
Zydus Lifesciences News
- 1 day ago - Top stocks to buy today: Stock recommendations for May 29, 2025 - The Times of India
- 9 days ago - Zydus share price: Nomura sees 29% upside, upbeat on US growth and vaccine contribution - Business Upturn
- 9 days ago - Zydus Lifesciences FY 25 net profit rises 17%; co declares Rs 11 dividend - The Times of India
- 9 days ago - Zydus Lifesciences Q4 results: Revenue rises 18% YoY; Net profit flat at Rs 1,171 crore - Business Upturn
- 10 days ago - Q4 Results Today, May 20: NHPC, Dixon Technologies, Gland Pharma, Zydus Lifesciences, Hindalco among companies reporting earnings - Business Upturn
- 15 days ago - Zydus receives EIR from USFDA for its Ambernath API manufacturing facility - Business Upturn
- 21 days ago - Zydus gets USFDA nod for generic version of Copaxone for treatment of Multiple Sclerosis - Business Upturn
- 4 weeks ago - Zydus gets USFDA final approval for Niacin Extended-Release Tablets - Business Upturn